This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Dopastatin
- DrugBank Accession Number
- DB16144
- Background
Dopastatin is under investigation in clinical trial NCT04335357 (TBR-760 in Adult Patients With Non-functioning Pituitary Adenomas).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Dopastatin (DB16144)
- Weight
- Average: 1694.21
Monoisotopic: 1692.784147935 - Chemical Formula
- C86H116N16O12S4
- Synonyms
- Not Available
- External IDs
- BIM-23A760
- TBR-760
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Amines
- Amino Acids, Peptides, and Proteins
- Benzene Derivatives
- Biogenic Amines
- Biogenic Monoamines
- Catecholamines
- Catechols
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hypothalamic Hormones
- Nerve Tissue Proteins
- Neuropeptides
- Pancreatic Hormones
- Peptide Hormones
- Peptides
- Phenols
- Pituitary Hormone Release Inhibiting Hormones
- Proteins
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- L32IM11DV4
- CAS number
- 868562-36-1
- InChI Key
- WLBJBODHTIKYSL-RXHQQAJBSA-N
- InChI
- InChI=1S/C86H116N16O12S4/c1-5-30-101-41-51(32-60-58-17-14-22-64-76(58)54(39-91-64)36-72(60)101)43-115-47-74(105)89-29-13-11-21-66(93-75(106)48-116-44-52-33-61-59-18-15-23-65-77(59)55(40-92-65)37-73(61)102(42-52)31-6-2)81(109)99-70-45-117-118-46-71(86(114)100-78(49(4)103)79(88)107)98-80(108)62(7-3)94-82(110)67(20-10-12-28-87)95-84(112)69(35-53-38-90-63-19-9-8-16-57(53)63)97-83(111)68(96-85(70)113)34-50-24-26-56(104)27-25-50/h8-9,14-19,22-27,38-40,49,51-52,60-62,66-73,78,90-92,103-104H,5-7,10-13,20-21,28-37,41-48,87H2,1-4H3,(H2,88,107)(H,89,105)(H,93,106)(H,94,110)(H,95,112)(H,96,113)(H,97,111)(H,98,108)(H,99,109)(H,100,114)/t49-,51-,52-,60-,61-,62?,66-,67+,68?,69-,70?,71+,72-,73-,78+/m1/s1
- IUPAC Name
- (2R)-N-[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-{[(1S,2R)-1-carbamoyl-2-hydroxypropyl]carbamoyl}-7-ethyl-16-[(4-hydroxyphenyl)methyl]-13-[(1H-indol-3-yl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-19-yl]-2,6-bis[2-({[(2R,4R,7R)-6-propyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(15),9,12(16),13-tetraen-4-yl]methyl}sulfanyl)acetamido]hexanamide
- SMILES
- [H][C@@]12CC3=CNC4=C3C(=CC=C4)[C@@]1([H])C[C@@H](CSCC(=O)NCCCC[C@@H](NC(=O)CSC[C@H]1CN(CCC)[C@]3([H])CC4=CNC5=C4C(=CC=C5)[C@@]3([H])C1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC3=CNC4=C3C=CC=C4)NC(=O)[C@H](CC3=CC=C(O)C=C3)NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)CN2CCC
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data2 Terminated Treatment Acromegaly 1 somestatus stop reason just information to hide 2 Terminated Treatment Carcinoid Syndrome 1 somestatus stop reason just information to hide 2 Unknown Status Treatment Non-functioning Pituitary Adenomas / Pituitary Tumor, Nonfunctioning 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00265 mg/mL ALOGPS logP 4.88 ALOGPS logP 3.2 Chemaxon logS -5.8 ALOGPS pKa (Strongest Acidic) 9.81 Chemaxon pKa (Strongest Basic) 10.36 Chemaxon Physiological Charge 3 Chemaxon Hydrogen Acceptor Count 15 Chemaxon Hydrogen Donor Count 16 Chemaxon Polar Surface Area 425.32 Å2 Chemaxon Rotatable Bond Count 33 Chemaxon Refractivity 464.79 m3·mol-1 Chemaxon Polarizability 185.66 Å3 Chemaxon Number of Rings 12 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at December 15, 2020 18:13 / Updated at December 20, 2020 03:37